Skip to content

Mepivacaine Vs. Bupivacaine Spinal for TKA

Mepivacaine Vs. Bupivacaine Spinal: Effect on Return of Motor Function, Time to Ambulation, and Length of Stay in Total Knee Arthroplasty

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05765682
Enrollment
160
Registered
2023-03-13
Start date
2023-03-13
Completion date
2024-08-25
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Knee Replacement

Brief summary

This study will enroll patients 18-75 years of age who are undergoing elective primary total knee replacement. The patients will be randomized to receive one of two spinal blocks: 1) mepivacaine or 2) bupivacaine. The primary goal is to determine which group arrives at recovery of motor function first. Ultimately, this study will explore if mepivacaine leads to earlier return of motor function and ultimately earlier movement and discharge times following total knee replacement.

Interventions

OTHERMepivacaine Spinal

spinal block using 60mg of mepivacaine

OTHERBupivacaine Spinal

spinal block using 10mg of bupivacaine

Sponsors

Medical University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Caregiver)

Masking description

Subject, surgeon, and care team members will be blinded to the assigned randomization group. The anesthesiologist will not be blinded.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Ages 18-75 years of age * Undergoing elective primary total knee arthroplasty

Exclusion criteria

* Inability to ambulate or impaired motor function in lower extremities prior to surgery * Contraindication to spinal anesthetic * Taking over 30mg oxycodone per day (or calculated MME equivalent) * Subjects that are unable or choose not to give informed consent * Known preoperative substance abuse * Pregnant women * Allergy to all opioids

Design outcomes

Primary

MeasureTime frameDescription
Time until return of motor function following spinal placementFrom anesthesia stop time until 7 days post-opThis will be defined as full strength with both 1) foot plantar and dorsiflexion and 2) hip flexion and 3) knee flexion in the non-operative extremity.

Secondary

MeasureTime frameDescription
Ambulationfrom anesthesia stop time until 7 days post-opTime to first ambulation and distance at first ambulation
Length of StayTime from anesthesia end time to when discharge order is written, up to 30 days post-opbased on anesthesia end time to time discharge order written
Side Effects0-48 hours post spinal placementSide effects such as Urinary retention, dizziness, symptomatic hypotension, transient neurologic symptoms
Pain ScoresPacu to 48 hours post-spinal placementVisual Analog Pain Score 0-100 pain scores at rest, and with movement. A lower pain score means a better outcome.

Other

MeasureTime frameDescription
Tourniquet useduring procedure for up to 7 days hours after procedure endsWhether or not a tourniquet is used during surgery will be recorded as yes or no.
Cement useduring procedure or up to 7 days hours after procedure endsWhether or not a cement is used during surgery will be recorded as yes or no.
Robotic or notduring procedure or up to 7 days hours after procedure endsWhether or not the procedure is robotic or not will be recorded as yes or no.
Preoperative opioid usewithin past 90 days at time of procedureUse of opioids in the pre-operative period converted to MME (morphine equivalent)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026